Is It Time To Reconsider Itron (ITRI) After The Recent Share Price Pullback?

  • For investors wondering whether Itron at around US$88.55 is starting to look like a bargain or is still priced for optimism, this article breaks down what the current share price may be implying about the stock's value.
  • The share price has slipped about 10% over the last week and 5.3% over the last month, even though the 3-year return sits at 65.8% and the 1-year return is a 19.8% decline.
  • Recent coverage has focused on Itron's position in power grid technology and smart metering, along with how the business fits into broader grid modernisation and efficiency themes. This kind of news helps explain why expectations around future projects and contracts can quickly shift sentiment, which often shows up in short-term price moves.
  • Itron currently has a valuation score of 6 out of 6, so next comes a closer look at what different valuation methods are saying about that score and why there may be an even better way to judge value by the end of this article.

Find out why Itron's -19.8% return over the last year is lagging behind its peers.

Advertisement

Approach 1: Itron Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes estimates of the cash a business could generate in the future and discounts those amounts back to today, aiming to translate long term cash flow potential into a present value per share.

For Itron, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows in $. The latest twelve month free cash flow is about $378.7 million. Analysts provide explicit forecasts out to 2028, where free cash flow is projected at $450.0 million. Simply Wall St then extrapolates further out to 2035, with annual projections ranging from about $304.9 million in 2026 to $601.5 million in 2035.

After discounting these projected cash flows back to today, the DCF model arrives at an estimated intrinsic value of about $163.64 per share. Compared with the recent share price around $88.55, this framework suggests Itron is trading at a 45.9% discount to that intrinsic value estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Itron is undervalued by 45.9%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks.

ITRI Discounted Cash Flow as at Apr 2026
ITRI Discounted Cash Flow as at Apr 2026

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Itron.

Approach 2: Itron Price vs Earnings

For a profitable business like Itron, the P/E ratio is a useful shorthand for how much investors are paying for each dollar of earnings. It ties directly to the current bottom line, which is usually more relevant for established, earnings generating companies than sales or book value alone.

What counts as a “fair” P/E depends on how the market views a company’s growth prospects and risk profile. Higher expected growth or lower perceived risk can support a higher P/E, while slower expected growth or higher risk often points to a lower, more cautious P/E range.

Itron currently trades on a P/E of 13.04x, compared with an Electronic industry average of 27.39x and a peer group average of 78.72x. Simply Wall St’s Fair Ratio for Itron is 19.59x. This Fair Ratio is a proprietary estimate of what the P/E could be, based on factors such as earnings growth, profit margins, industry, market cap and company specific risks. Because it adjusts for these fundamentals, it can be more tailored than a simple comparison against industry or peer averages.

Set against this Fair Ratio, Itron’s current P/E of 13.04x sits below the 19.59x level.

Result: UNDERVALUED

NasdaqGS:ITRI P/E Ratio as at Apr 2026
NasdaqGS:ITRI P/E Ratio as at Apr 2026

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Itron Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Think of a Narrative as your own clear story for Itron that connects what you believe about grid modernisation, revenue, earnings and margins to a forecast, and then to a Fair Value on Simply Wall St’s Community page. For example, one investor might build a more bullish Itron Narrative closer to the US$136.80 Fair Value used by analysts. Another might plug in more cautious revenue and earnings assumptions that sit nearer the lower US$318.2m earnings estimate. As fresh information such as new contracts, earnings results or guidance comes in, these Narratives are updated so you can quickly compare your Fair Value against the current price and decide whether Itron still fits your view or if the story has changed enough to rethink your timing.

Do you think there's more to the story for Itron? Head over to our Community to see what others are saying!

NasdaqGS:ITRI 1-Year Stock Price Chart
NasdaqGS:ITRI 1-Year Stock Price Chart

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

New: AI Stock Screener & Alerts

Our new AI Stock Screener scans the market every day to uncover opportunities.

• Dividend Powerhouses (3%+ Yield)
• Undervalued Small Caps with Insider Buying
• High growth Tech and AI Companies

Or build your own from over 50 metrics.

Explore Now for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com

About NasdaqGS:ITRI

Itron

A technology, solutions, and service company, provides end-to-end solutions that help manage energy, water, and smart city operations worldwide.

Very undervalued with proven track record.

Advertisement

Weekly Picks

LO
Lou_Basenese
OPTH logo
Lou_Basenese on Optimi Health ·

The Only Psychedelic Company Already Selling MDMA and Psilocybin to Real Patients, Yet Priced Like It Doesn’t Exist

Fair Value:US$1157.5% undervalued
47 users have followed this narrative
2 users have commented on this narrative
7 users have liked this narrative
WE
WealthAP
NOVO B logo
WealthAP on Novo Nordisk ·

Novo Nordisk (NVO): Is the "Easy Growth" Story Over?

Fair Value:DKK 407.7721.4% undervalued
68 users have followed this narrative
0 users have commented on this narrative
8 users have liked this narrative
VA
ValueInvestingSubstack
ZTS logo
ValueInvestingSubstack on Zoetis ·

Zoetis down -50% over the past year

Fair Value:US$92.9218.9% undervalued
23 users have followed this narrative
0 users have commented on this narrative
9 users have liked this narrative
CE
CentryResearch
LEU logo
CentryResearch on Centrus Energy ·

Centrus Energy: The Next Nuclear Bottleneck Isn't Reactors. It's Fuel.

Fair Value:US$19013.7% undervalued
24 users have followed this narrative
0 users have commented on this narrative
10 users have liked this narrative

Updated Narratives

WI
WisetoWealth
PYPL logo
WisetoWealth on PayPal Holdings ·

The Underrated Transformation of a Digital Payments Giant

Fair Value:US$90.3137.8% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
BL
Blagget
TERA logo
Blagget on Terra Balcanica Resources ·

The C$4M Explorer Positioned to Become Europe's First Antimony Mine

Fair Value:CA$0.487.5% undervalued
2 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
DA
CHTR logo
david_6nroa on Charter Communications ·

Charter is undervalued - Here's why.

Fair Value:US$87.0741.6% overvalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

CU
MSFT logo
CubanEros on Microsoft ·

A wonderful business at reasonable price.

Fair Value:US$419.919.1% undervalued
81 users have followed this narrative
0 users have commented on this narrative
6 users have liked this narrative
OS
oscargarcia
NVDA logo
oscargarcia on NVIDIA ·

The company that went from selling GPUs to gamers to becoming the AI arms dealer of the 21st century.

Fair Value:US$28026.1% undervalued
185 users have followed this narrative
9 users have commented on this narrative
15 users have liked this narrative
BE
PYPL logo
benjamin_lvieq on PayPal Holdings ·

PayPal: PayPal Doesn't Need to Grow – It Needs to Stop Falling – A Mispriced Cash Machine With a Cannibal Buyback

Fair Value:US$6513.6% undervalued
72 users have followed this narrative
2 users have commented on this narrative
11 users have liked this narrative

Trending Discussion

DE
TDOC logo
derek_3wsdg on Teladoc Health ·

You’ve overlooked the activist investor factor. Travis Cocke’s Voss has announced 5% ownership through a 13G filing. They’ve added to that 5% since, and in doing so, have created a structural trap door for 27.42 Million Shares actively sold short. Chuck will announce lots of positives on July 29 but it’s what Voss announces shortly after that will rock the overextended Teledoc shorts. The Walmart partnership is the tip of the iceberg. The market is missing the sheer regulatory and enterprise friction of modern corporate healthcare. Teladoc isn't a "consumer app"; it is the primary digital infrastructure integrated directly into the legacy backends of Tier-1 insurance companies and fortune 500 employers, covering 105 million+ lives. Teladoc is acting as the digital top-of-funnel engine for the world's largest retailer. If Voss pushes the narrative that Teladoc is effectively the outsourced digital brain of Walmart's entire healthcare footprint, the fair value shifts from a basic health multiple to an enterprise distribution premium. Additionally , we are in a structural gold rush for high-quality, legally compliant, longitudinal medical data to train vertical healthcare AI models. Large technology hyperscalers and pharmaceutical giants cannot simply scrape the internet for this; they need structured clinical inputs. Teladoc sits on one of the largest de-identified virtual medical datasets on earth. From the activist playbook , we’ll see Voss demand the immediate creation of a Data & Diagnostics Licensing Division, transforming a legacy liability into an incredibly high-margin, pure-software data asset that requires zero human clinician hours to scale. Chuck is doing great work and deserves credi5 for the Teledoc turnaround but it will be Travis Cocke who will be responsible for a share price way beyond your $15 valuation.

1
|
0